AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31940543 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-layer-GA-SVM (Genetic Algorithm-Support Vector Machine)
Number of subjects: 30
Study 31940543 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method (fNIRS technology)
Number of subjects: 30
Study 30472431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min) applied bilaterally over the prefrontal cortex
Number of subjects: 0
Study 30472431 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not specified in detail)
Number of subjects: 0
Study 28183288 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (Ph-Tx)
Number of subjects: 72
Study 28183288 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint therapy (Sp-Tx)
Number of subjects: 72
Study 26764392 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care plan using a functional geriatric approach
Number of subjects: 225
Study 26764392 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 225
Study 25095811 — intervention group
Group type: EXPERIMENTAL
Intervention: Two servings of Camembert cheese (2 x 30g) per day for 5 weeks
Number of subjects: 159
Study 25095811 — intervention group
Group type: COMPARATOR
Intervention: Two full-fat yoghurts (2 x 125g) per day for 5 weeks
Number of subjects: 159
Study 21963104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG)
Number of subjects: 704
Study 19257867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT) with moderate intensity (50-60% of power achieved during exercise test), 45-60 min duration, 3 times a week.
Number of subjects: 392
Study 19257867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 392
Study 19257867 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy for IHD)
Number of subjects: 392
Study 17907859 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone‐based continuing care for 12 weeks
Number of subjects: 224
Study 17907859 — intervention group
Group type: COMPARATOR
Intervention: group counseling continuing care
Number of subjects: 224
Study 17907859 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help involvement during treatment
Number of subjects: 224
Study 17907859 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐efficacy and commitment to abstinence 3 months after treatment
Number of subjects: 224
Study 17907859 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help beliefs
Number of subjects: 224
Study 17907859 — intervention group
Group type: EXPERIMENTAL
Intervention: social support
Number of subjects: 224
Study 14684972 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF toothpaste (1,400 ppm F)
Number of subjects: 10
Study 14684972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste containing AmF and NaF
Number of subjects: 10
Study 14684972 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste (500, 1,000 and 1,450 ppm F)
Number of subjects: 10
Study 14684972 — intervention group
Group type: COMPARATOR
Intervention: SMFP toothpaste (525, 1,000, 1,450 ppm F)
Number of subjects: 10
Study 14684972 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free dentifrice
Number of subjects: 10
Study 9676755 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly at 10 AM
Number of subjects: 23
Study 9676755 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly at 6 PM
Number of subjects: 23
Study 9676755 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MTX administration times (10 AM vs 6 PM)
Number of subjects: 23
Study 7852220 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 300
Study 29643163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal Dex (0.5 µg/kg)
Number of subjects: 30
Study 29643163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dex (0.5 µg/kg)
Number of subjects: 30
Study 29643163 — intervention group
Group type: COMPARATOR
Intervention: Control (Intravenous saline)
Number of subjects: 30
Study 29643163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal Dex
Number of subjects: 30
Study 28333551 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week group program of 2-hour weekly sessions addressing mindfulness of food choices facilitated by a trained dietitian and social worker.
Number of subjects: 30
Study 28333551 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 30
Study 25883031 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM) administration
Number of subjects: 162
Study 25883031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhTM administration)
Number of subjects: 162
Study 23260769 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 42
Study 23260769 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolic acid B (SA‐B)
Number of subjects: 42
Study 23260769 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) + Salvianolic acid B (SA‐B)
Number of subjects: 42
Study 21161250 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle resection combined with rotator cuff repair (Group 1)
Number of subjects: 83
Study 21161250 — intervention group
Group type: COMPARATOR
Intervention: Isolated rotator cuff repair (Group 2)
Number of subjects: 83
Study 20032902 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming (Group 1)
Number of subjects: 45
Study 20032902 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (Group 2)
Number of subjects: 45
Study 20032902 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Exercise (CE) (Group 3)
Number of subjects: 45
Study 17199537 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy using non-resorbable expanded polytetrafluoroethylene membranes
Number of subjects: 31
Study 17199537 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy using bioabsorbable barriers
Number of subjects: 31
Study 17199537 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy
Number of subjects: 31
Study 15495785 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house coordinator intervention
Number of subjects: 8
Study 15495785 — intervention group
Group type: COMPARATOR
Intervention: Control (centers without in-house coordinators)
Number of subjects: 8
Study 11559318 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice daily for 2 weeks, followed by 80 mg trimethoprim and 400 mg sulfamethoxazole twice daily for 5.5 months
Number of subjects: 22
Study 11559318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9692305 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied linoleic acid
Number of subjects: 0
Study 9692305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8148129 — intervention group
Group type: EXPERIMENTAL
Intervention: System for Augmenting Language (SAL)
Number of subjects: 13
Study 3169108 — intervention group
Group type: EXPERIMENTAL
Intervention: SR verapamil 240 mg tablets administered every 12 h for 6 consecutive weeks
Number of subjects: 12
Study 3169108 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 12 h for 6 consecutive weeks
Number of subjects: 12
Study 29422350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic (CoC)
Number of subjects: 58
Study 29422350 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene (CoP)
Number of subjects: 58
Study 27482958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 44
Study 25236582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (resistance and aerobic training, 3 days per week for 12 months)
Number of subjects: 20
Study 25236582 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 20
Study 25236582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 20
Study 24041351 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Diary
Number of subjects: 172
Study 21439962 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition for 30 days
Number of subjects: 78
Study 21439962 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition for 30 days
Number of subjects: 78
Study 19005898 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (5 mg/day) at bedtime
Number of subjects: 113
Study 19005898 — intervention group
Group type: COMPARATOR
Intervention: Torasemide (5 mg/day) upon awakening
Number of subjects: 113
Study 16646353 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) training
Number of subjects: 38
Study 16646353 — intervention group
Group type: COMPARATOR
Intervention: Concentric (CON) training
Number of subjects: 38
Study 12738159 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol 600 microg
Number of subjects: 295
Study 12738159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 microg
Number of subjects: 295
Study 12738159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 600 microg
Number of subjects: 295
Study 12738159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rectal groups (400 and 600 microg)
Number of subjects: 295
Study 12738159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (both doses)
Number of subjects: 295
Study 10978404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal dialysis (TPD)
Number of subjects: 17
Study 10978404 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling PD (CCPD)
Number of subjects: 17
Study 8797943 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque, 320 mgI/ml)
Number of subjects: 117
Study 8797943 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (Solutrast, 370 mgI/ml)
Number of subjects: 117
Study 1616156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 24
Study 1616156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24
Study 1616156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg three times a day
Number of subjects: 495
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 495
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 37.5 mg twice daily
Number of subjects: 495
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg three times a day
Number of subjects: 495
Study 6237623 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 495
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg twice daily
Number of subjects: 495
Study 6237623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Captopril combination
Number of subjects: 495
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking behaviour (≥6 drinks per occasion)
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmful drinking levels
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to ART
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking risk factors
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking risk based on beverage type
Number of subjects: 623
Study 31635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of drinking
Number of subjects: 623
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 316
Study 29447773 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin only
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor only
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (DAPT + oral anticoagulant)
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) only
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC plus aspirin
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC plus P2Y12 inhibitor
Number of subjects: 316
Study 29447773 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents without OAC
Number of subjects: 316
Study 27627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 0
Study 27627785 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin
Number of subjects: 0
Study 25011657 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group (received 2 text messages twice a day for 12 weeks)
Number of subjects: 160
Study 25011657 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive any messages)
Number of subjects: 160
Study 22747980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial CD133(+) bone marrow stem cell injection in combination with coronary artery bypass grafting
Number of subjects: 0
Study 22747980 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 0
Study 20683172 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 71
Study 20683172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 17066227 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 286
Study 17066227 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 286
Study 14992701 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 47
Study 14992701 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 47
Study 14992701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral calcaneal fractures
Number of subjects: 47
Study 11546663 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation during and up to 2 h postexercise
Number of subjects: 10
Study 11546663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9565856 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year cancer course (n=17)
Number of subjects: 33
Study 9565856 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 33
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (800 micrograms kg‐1 in two divided doses)
Number of subjects: 36
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (200 micrograms kg‐1)
Number of subjects: 36
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (300 micrograms kg‐1)
Number of subjects: 36
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (500 micrograms kg‐1)
Number of subjects: 36
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (600 micrograms kg‐1)
Number of subjects: 36
Study 7925204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (680 micrograms kg‐1)
Number of subjects: 36
Study 3287970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 335
Study 3287970 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 335
Study 3287970 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 335
Study 31710635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (RT30) at 30% of maximal strength (1RM)
Number of subjects: 11
Study 31710635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (RT80) at 80% of maximal strength (1RM)
Number of subjects: 11
Study 31710635 — intervention group
Group type: COMPARATOR
Intervention: Control session without exercise
Number of subjects: 11
Study 29992026 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 19
Study 29992026 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 19
Study 29992026 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 extensive and intermediate metabolizers
Number of subjects: 19
Study 29992026 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 poor metabolizers
Number of subjects: 19
Study 29992026 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity of CYP2B6 *5 and *6
Number of subjects: 19
Study 26795378 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental support programme (6 months duration) including health information for parents, motivational interviewing, and teacher-led activities
Number of subjects: 378
Study 26795378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 378
Study 24366980 — intervention group
Group type: EXPERIMENTAL
Intervention: LBR-101 (any dose)
Number of subjects: 139
Study 24366980 — intervention group
Group type: EXPERIMENTAL
Intervention: LBR-101 (1000 mg or higher)
Number of subjects: 139
Study 24366980 — intervention group
Group type: EXPERIMENTAL
Intervention: LBR-101
Number of subjects: 139
Study 24366980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 23199187 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy (RATE)
Number of subjects: 112
Study 23199187 — intervention group
Group type: COMPARATOR
Intervention: Open three-stage transthoracic esophageal resection
Number of subjects: 112
Study 23199187 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications (grade 2 and higher)
Number of subjects: 112
Study 19207627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive coparenting behavior
Number of subjects: 92
Study 19207627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low effortful control with high supportive coparenting behavior
Number of subjects: 92
Study 17443097 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP)
Number of subjects: 173
Study 17443097 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 173
Study 15897552 — intervention group
Group type: EXPERIMENTAL
Intervention: AC followed by PTX
Number of subjects: 3060
Study 15897552 — intervention group
Group type: COMPARATOR
Intervention: AC
Number of subjects: 3060
Study 11894615 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended GP information routine
Number of subjects: 20
Study 11894615 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 20
Study 10102953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 15 mg/day
Number of subjects: 24
Study 10102953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg/day
Number of subjects: 24
Study 10102953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 24
Study 10102953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 4.5 mg b.d.
Number of subjects: 24
Study 10102953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10102953 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 20 mg/day
Number of subjects: 24
Study 7805221 — intervention group
Group type: COMPARATOR
Intervention: Encainide, flecainide, and moricizine at two different dose levels (CAST-I); Moricizine alone at three dose levels (CAST-II).
Number of subjects: 2941
Study 7805221 — intervention group
Group type: EXPERIMENTAL
Intervention: Easily suppressed ventricular arrhythmias (after adjusting for other variables).
Number of subjects: 2941
Study 2319047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 17
Study 2319047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate
Number of subjects: 17
Study 2319047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 310511 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 100
Study 310511 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 30419298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 500
Study 27246522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g of long-chain n-3 polyunsaturated fatty acids)
Number of subjects: 533
Study 27246522 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 533
Study 27246522 — intervention group
Group type: COMPARATOR
Intervention: No oil
Number of subjects: 533
Study 25461496 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session core weight loss intervention
Number of subjects: 450
Study 25461496 — intervention group
Group type: COMPARATOR
Intervention: 12-session maintenance component
Number of subjects: 450
Study 25438678 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (OLAI)
Number of subjects: 0
Study 25438678 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 0
Study 22994863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher Select sirolimus-eluting stent (SES)
Number of subjects: 281
Study 22994863 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty (BA)
Number of subjects: 281